Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 9.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,790 shares of the company’s stock after purchasing an additional 660 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Johnson & Johnson were worth $1,197,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of the stock. LCM Capital Management Inc grew its position in Johnson & Johnson by 0.7% in the fourth quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock worth $1,667,000 after buying an additional 61 shares during the last quarter. Arbor Investment Advisors LLC grew its position in Johnson & Johnson by 2.3% in the fourth quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock worth $476,000 after buying an additional 61 shares during the last quarter. Sierra Capital LLC grew its position in Johnson & Johnson by 0.6% in the fourth quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock worth $1,773,000 after buying an additional 61 shares during the last quarter. Lockerman Financial Group Inc. grew its position in Johnson & Johnson by 2.4% in the fourth quarter. Lockerman Financial Group Inc. now owns 2,684 shares of the company’s stock worth $474,000 after buying an additional 62 shares during the last quarter. Finally, OneAscent Financial Services LLC grew its position in Johnson & Johnson by 3.3% in the first quarter. OneAscent Financial Services LLC now owns 1,986 shares of the company’s stock worth $308,000 after buying an additional 63 shares during the last quarter. Institutional investors own 67.57% of the company’s stock.
Insider Activity
In other news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares in the company, valued at approximately $15,092,484. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,163 shares of company stock worth $7,928,856. 0.20% of the stock is owned by corporate insiders.
Johnson & Johnson Trading Up 0.5 %
Shares of NYSE:JNJ opened at $174.48 on Friday. The firm has a market capitalization of $453.43 billion, a P/E ratio of 35.32, a price-to-earnings-growth ratio of 2.91 and a beta of 0.55. The firm has a fifty day moving average of $161.76 and a two-hundred day moving average of $161.21. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The business had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 37.01%. Johnson & Johnson’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.59 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.76 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be issued a dividend of $1.19 per share. The ex-dividend date is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.73%. Johnson & Johnson’s dividend payout ratio is currently 96.36%.
Wall Street Analyst Weigh In
Several research analysts have issued reports on the stock. Atlantic Securities decreased their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 19th. TheStreet lowered shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Credit Suisse Group raised their price objective on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Citigroup started coverage on shares of Johnson & Johnson in a research note on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price objective for the company. Finally, Raymond James raised their price objective on shares of Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a research note on Monday, July 24th. Eight analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $171.60.
Johnson & Johnson Profile
(Free Report)
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Recommended Stories
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
